首页> Annals of the rheumatic diseases> Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).

导出 LinkOut

翻译打印收藏纠错

第一作者： P M,Meiners

第一单位： Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

作者： P M,Meiners ^[1] ; A,Vissink ^[1] ; F G M,Kroese ^[2] ; F K L,Spijkervet ^[1] ; N Sillevis,Smitt-Kamminga ^[3] ; W H,Abdulahad ^[2] ; J,Bulthuis-Kuiper ^[2] ; E,Brouwer ^[2] ; S,Arends ^[2] ; H,Bootsma ^[2]

作者单位： Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[1] Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[2] Department of Opthalmology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[3]

关键词 DMARDs (biologic)Disease Activity Outcomes Research Sj?gren's Syndrome T Cells